ANZATAX

This brand name is authorized in Hong Kong, New Zealand, Singapore, Tunisia, Turkey, South Africa

Active ingredients

The drug ANZATAX contains one active pharmaceutical ingredient (API):

1 Paclitaxel UNII P88XT4IS4D - PACLITAXEL

Paclitaxel is an antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilises microtubules by preventing depolymerisation. This stability results in the inhibition of the normal dynamic reorganisation of the microtubule network that is essential for vital interphase and mitotic cellular functions. Read about Paclitaxel

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ANZATAX Concentrate for solution for injection	Pharmaceutical Benefits Scheme (AU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01CD01	Paclitaxel	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01C Plant alkaloids and other natural products → L01CD Taxanes
Discover more medicines within L01CD01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: HK	Department of Health Drug Office	Identifier(s): 40639, 40640
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 7125
Country: SG	Health Sciences Authority	Identifier(s): 09539P
Country: TN	Direction de la Pharmacie et du Médicament	Identifier(s): 11413011H, 11413012H
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699643770092, 8699643770108, 8699643770214, 8699643770252
Country: ZA	Health Products Regulatory Authority	Identifier(s): 36/26/0255